EAN 2021 | Low serum contactin-1 predicts disability progression in MS
Charlotte Teunissen, PhD, VU University Medical Center, Amsterdam, The Netherlands, shares the findings of a case-control study assessing serum contactin-1 (sCNTN1) as a novel biomarker in natalizumab-treated relapsing/remitting multiple sclerosis (RRMS). Serum contactin levels were measured in 89 patients with RRMS at baseline and throughout follow-up and compared to over 200 healthy controls. Disease progression was assessed according to EDSS-plus criteria. The study demonstrated that median sCNTN1 levels in patients with RRMS were significantly lower compared to healthy controls. Additionally, baseline and 12-month sCNTN1 levels were significantly lower in those with progressive disease. These findings indicate that sCNTN1 concentrations are linked in long-term disability progression and may represent a useful liquid biomarker for RRMS. This interview took place during the European Academy of Neurology 2021 congress.
Disclosures
Research of Prof. Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association.
Prof. Teunissen is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds.
Prof. Teunissen has a collaboration contract with ADx Neurosciences and Quanterix, performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon.
